ReviewSeminars in oncology2017

A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab.

Petros Fessas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.